Navigation Links
Rare skin tumor responds better to treatment than melanoma
Date:2/2/2009

University of Michigan Health System researchers have published new data to help answer two dreaded questions: "Is it cancer?" and "What type of treatment should I have?"

Cancer is the primary concern when abnormal skin lesions are detected. Macroscopic and microscopic features of a lesion usually provide clues about whether it is benign or malignant. However, the distinction is not always clear-cut, and doctors are faced with the question of how to best treat such patients.

The quandary is especially pronounced in atypical spitzoid tumors (ASTs), a rare proliferation of pigmented skin cells. ASTs have many features of melanoma, a potentially deadly form of skin cancer. ASTs tend to appear in patients who are much younger than the age when skin cancer traditionally occurs, which makes determining whether the lesion is malignant or benign even more difficult.

The new research, led by the University of Michigan Multidisciplinary Melanoma Program and published in the journal Cancer, suggests that ASTs behave differently from other types of melanoma. This finding could eventually lead to fundamental changes in the way ASTs are treated.

"As patients with AST appear to do better than conventional melanoma after similar treatment, we are now able to provide some reassurance to concerned parents and loved ones about the implications of the diagnosis," says lead study author Mathew Ludgate, MBChB, FRACP, assistant professor in the U-M Multidisciplinary Melanoma Program.

Although ASTs are rare, the U-M Multidisciplinary Melanoma Program has considerable experience as a preeminent national referral center. ASTs are an increasing challenge for physicians, as the number of ASTs diagnosed throughout the country appears to be increasing for unknown reasons. The researchers focused on long-term outcomes of ASTs to formulate improved evidence-based treatment guidelines.

Doctors generally treat patients with AST similar to malignant melanoma by surgically removing the lesion and in many cases also with a sentinel lymph node biopsy. The sentinel lymph node biopsy involves the removal and evaluation of one or a few lymph nodes nearest the skin lesion to determine whether the skin lesion has spread to the lymph nodes.

Ludgate and his team analyzed U-M's unique comprehensive melanoma database that has been collecting data for almost two decades for all cases of ASTs of uncertain biological potential between 1994 and 2007. Data were examined to learn the clinical features of a patient, whether the patient underwent a lymph node biopsy and the histological features of the tumor.

Of the 67 patients in the study, 57 had undergone wide excision and sentinel lymph node biopsy, and 27 biopsies were positive.

All 27 of AST patients with positive sentinel node biopsy are alive and disease-free at an average of about 44 months follow-up, researchers note.

"If AST were a form of melanoma, we would expect that at least some of the patients would have had the AST recur throughout the body by this time" Ludgate explains. "This study provides evidence that although ASTs have some features of melanoma microscopically, they do not behave as aggressively."

These findings can be interpreted in three ways, Ludgate says. "The first is that AST is not cancer at all, but has some ability to spread. The second possibility is that because ASTs often occur in younger people with intact immune systems, the body is able to successfully fight off the beginnings of metastatic disease. The third possibility is that AST is potentially deadly but removal of the primary AST lesion and the sentinel lymph node biopsy is curative."

Each of these possibilities is considered in the treatment strategy developed collectively as a result of this study. One result of this new strategy is that not every patient with AST must undergo a complete lymph node dissection or treatment with interferon-alpha after a positive sentinel lymph node biopsy, depending on the degree of lymph node involvement and the age of the patient. This is important as complete lymph node dissection is a more extensive surgery than a sentinel lymph node biopsy alone, and has considerable more risk of long term side effects.

Given the difficulty determining whether AST is benign or malignant, Ludgate notes, the melanoma team plans to "identify the molecular profile of ASTs to further characterize the true behavior of these tumors."


'/>"/>

Contact: Katie Vloet
kgazella@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein
2. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
3. Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors
4. Breast cancer drug shows promise for treating, preventing progestin-dependent tumors
5. New laser for neurosurgery allows greater precision and efficiency for removal of complex tumors
6. Gene may lead to early onset of brain tumor
7. New Institute Targets Brain Tumor Survival
8. New institute targets brain tumor removal
9. New criteria for measuring tumor size and progression will help ease workloads in clinical trials
10. David Welch, Friend, Advocate, Inspiration, Loses Courageous Battle to Brain Tumor
11. Gene therapy eliminates brain tumors through selective recruitment of immune cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... introducing the Aerolib Learning Management System: an On-demand E-learning system for Clinical ... and Hospital Administration that is based on Aerolib`s successful education methodology of ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... SF expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, ... growing demand of physicians and patients throughout the United States for high-quality human ...
(Date:1/19/2017)... ... 2017 , ... This month, the CEO and Clinical Director of Sober Living ... center in Delray Beach, Florida has been changed from Sober Living Outpatient to ‘SLO ... Seymour Hoffman and Chris Farley are dying from heroin overdoses, but thousands of unnamed ...
(Date:1/19/2017)... ... 19, 2017 , ... WhoHaha , a digital media company dedicated to ... (AHA) to produce a three-part video series that uses humor to highlight ways to ... launch of AHA’s Healthy For Good™ movement, which is designed to inspire all Americans ...
(Date:1/19/2017)... ... 2017 , ... Cosmetic Town, an online plastic surgery community, begins 2017 with ... easier for their readers to get the information they desire. The procedures are now ... techniques used on those particular areas. , “We are excited to streamline our listings ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , , Marks E-QURE , ... agreement, following similar agreements in Israel and ... 5 billion global market ... leader in medical devices for the treatment of advanced wound care, announced today ... in Colombia for the Company,s patented Bio-electrical Signal Therapy ...
(Date:1/19/2017)... Jan. 18, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
Breaking Medicine Technology: